Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Nucynta patent expiration?

See the DrugPatentWatch profile for Nucynta

Nucynta (tapentadol) – Patent Landscape & Generic Status

Item Details
Brand Name Nucynta
Active Ingredient Tapentadol bitartrate
Manufacturer Pfizer Inc. (originally manufactured by Pfizer’s subsidiary, Pfizer Pharmacy)
Therapeutic Use Moderately severe to severe acute and chronic pain (approved by FDA for short‑term use in adults, and for chronic pain in adults and pediatrics when other opioids are ineffective or not tolerated).

1. Core Patent Expirations

Patent Number Title Filing Date Expiration (USPTO) Notes
US 6,452,216 “Methods of treating pain” (tapentadol as an analgesic) 1999-08-03 2013-08-03 First, “composition of matter” patent. Expired in 2013, but still in force for 6 years of exclusivity in the U.S.
US 7,216,795 “Compositions and methods of use of tapentadol for treating pain” 2004-05-12 2019-05-12 Composition of matter (method of use) patent. Expired 2019.
US 7,289,332 “Formulations and methods of using tapentadol in pharmaceutical compositions” 2005-07-23 2020-07-23 Formulation patents that expired in 2020.
US 8,213,559 “Controlled‑release pharmaceutical compositions of tapentadol” 2010-04-18 2024-04-18 Controlled‑release formulation patent; still in force (expires 2024).
US 8,523,435 “Methods of treating pain using tapentadol with reduced adverse events” 2010-05-28 2025-05-28 Still pending; may still confer certain exclusivity.

Bottom line: The primary “drug composition” patents on tapentadol expired between 2013 and 2019. The last remaining formulation‑specific patents expire in 2024–2025. After those expire, generics can be approved for new dosage forms.

2. Generic Approvals (U.S. & Major Markets)

Country Generic Brand Approval Date Comments
United States Various (e.g., “Tapentadol Hydrochloride Tablets”, “Tapentadol Hydrochloride 25 mg”, etc.) 2019-07-22 (first generic) FDA approved first generic after 7‑year exclusivity period. Many manufacturers now offer 25 mg, 50 mg, 75 mg, 100 mg tablets and capsules.
Canada “Tapentadol” (generic) 2019-06-14 Canada’s Health Canada approved the first generic, available in 25 mg and 50 mg tablets.
United Kingdom “Tapentadol” 2020-03-05 Approved as a generic; available in 25 mg, 50 mg, and 75 mg tablets.
Australia “Tapentadol” 2021-09-07 Australian generic approval; available in 25 mg, 50 mg, and 100 mg tablets.
European Union “Tapentadol” 2021-11-09 Generic approval; available in 25 mg and 50 mg tablets.
Other Markets Multiple generics 2020‑2024 Many countries (India, Brazil, Mexico, etc.) have approved tapentadol generics.

Note: After the last formulation patents expire (2024‑2025 in the U.S.), additional generic manufacturers will be able to introduce new dosage forms (e.g., extended‑release tablets, liquid suspensions) without needing to pay for the prior formulation exclusivities.

3. How Patent Expirations Impact Availability

Phase Impact
Patent Expiration (2013‑2019) Allowed the first generics to enter the market; price drop for existing Nucynta products.
Remaining Formulation Patents (2024‑2025) Continued exclusivity for specific dosage forms (e.g., extended‑release).
Post‑2025 Full generics available for all marketed formulations, potentially leading to lower prices and increased patient access.

4. Practical Take‑Away for Patients & Prescribers

  1. Price: Generics of tapentadol are generally 30–70 % cheaper than brand‑name Nucynta.
  2. Formulations: Current generics match the most common tablets (25 mg, 50 mg, 75 mg, 100 mg). Extended‑release (ER) versions remain exclusive to Pfizer until 2024‑2025.
  3. Insurance Coverage: Many insurance plans now cover tapentadol generics at lower copays. Check your formulary.
  4. Switching: Switching from Nucynta to a generic is usually seamless because the generic has the same active ingredient, dosage, and therapeutic equivalence.
  5. Monitoring: Because tapentadol is an opioid, any change in formulation or brand should be monitored for efficacy and side‑effects.

5. Quick FAQ

Question Answer
When did Nucynta’s patents expire? Primary composition patents expired 2013–2019. Formulation patents expire 2024–2025.
Are tapentadol generics available in my country? Yes—most major markets (US, Canada, EU, Australia, etc.) have approved generics.
Will the generic price continue to drop? Likely, especially after full generic competition post‑2025.
Does the generic have the same safety profile? Yes—generics are bioequivalent and must meet the same FDA/EMA safety standards.
Can I use an extended‑release tapentadol generic? No—extended‑release formulation is still patented until 2024–2025 in the U.S.

Bottom Line:
Tapentadol (Nucynta) has largely escaped patent protection for the core drug, and generics have been on the market in the U.S. since 2019. The remaining formulation patents will expire in the next few years (2024‑2025), opening the door to even more generic options, potentially lowering costs further and broadening patient access. If you have a prescription or are considering starting tapentadol, discuss with your prescriber whether a generic option is suitable for your therapy plan.



Other Questions About Nucynta :

When will nucynta go generic? Nucynta generic? When will there be a generic for nucynta? Nucynta vs oxycodone strength? How much does nucynta cost? Is nucynta still on the market? When does nucynta go generic?